Join the club for FREE to access the whole archive and other member benefits.

Selah Therapeutics launched to focus on ketone-based therapies for heart disease

13-May-2022

Key points from article :

Juvenescence and the Buck Institute for Research on Aging announced a joint venture with the formation of Selah Therapeutics Ltd.

Focus on developing first-in-class novel ketone-based therapies for chronic diseases of aging with first priority in heart disease.

Based on research conducted on ketones in the labs of Eric Verdin, John Newman, and Brianna Stubbs at the Buck.

Ketosis is a natural metabolic state that has mechanisms directly impacting hallmarks of aging.

“Selah’s mission is focused on developing and commercializing products that have strong scientific evidence-" says Jeff Madwed, Executive Director of Juvenescence’s JuvTherapeutics Division.

Global keto market is expected to rise to $14.75 billion by 2027.

 It’s not just about losing weight, as this new company plans to demonstrate.

Eric Verdin, Buck President and CEO says the new venture will be able to bring an important new therapeutic option to cardiovascular patients.

Treatment options for diseases of aging - from the makers of metabolic switch

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Academic

Lead Translational Scientist at Buck Institute for Research on Aging

Institute

Independent biomedical research institute focused on aging

Academic

CEO & President at Buck Institute for Research on Aging.

Company Representative

Executive Director of Juvenescence’s JuvTherapeutics Division

Health Professional

Geriatrician, basic science researcher, and educator at the Buck Institute and the UCSF

Company

Developing therapies against different aging related diseases.

Company

Company focused on novel ketone-based therapies for the treatment of heart diseases